Canaccord lowered the firm’s price target on Privia Health to $41 from $44 and keeps a Buy rating on the shares. The firm views Privia as an attractive long-term opportunity considering its diversified book-of-business, lower risk profile value-based care strategy, and significant room for new market expansion opportunities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRVA:
- Privia Health Reports Third Quarter 2023 Financial Results; Announces New Market Entry in South Carolina
- Privia Health reports Q3 adjusted EPS 17c, consensus 5c
- Is PRVA a Buy, Before Earnings?
- Privia Health price target lowered to $27 from $32 at Stephens
- Privia Health price target lowered to $30 from $40 at BTIG
